Bellerophon Therapeutics (NASDAQ:BLPH) Stock Rating Lowered by Zacks Investment Research


Share on StockTwits

Zacks Investment Research cut shares of Bellerophon Therapeutics (NASDAQ:BLPH) from a hold rating to a sell rating in a report published on Monday morning, Zacks.com reports.

According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “

Separately, Maxim Group reiterated a buy rating and issued a $22.00 target price on shares of Bellerophon Therapeutics in a research report on Friday, November 6th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company has a consensus rating of Buy and an average price target of $26.50.

Bellerophon Therapeutics stock opened at $7.06 on Monday. The company has a 50-day simple moving average of $6.95 and a 200-day simple moving average of $9.82. The firm has a market capitalization of $67.06 million, a P/E ratio of -2.13 and a beta of -0.29. Bellerophon Therapeutics has a one year low of $3.19 and a one year high of $26.00.

Bellerophon Therapeutics (NASDAQ:BLPH) last announced its earnings results on Thursday, November 5th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.83) by ($0.01). As a group, research analysts expect that Bellerophon Therapeutics will post -3.15 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of BLPH. First Trust Advisors LP acquired a new position in Bellerophon Therapeutics during the third quarter valued at approximately $208,000. WINTON GROUP Ltd purchased a new position in shares of Bellerophon Therapeutics during the third quarter valued at about $127,000. Nuveen Asset Management LLC purchased a new position in shares of Bellerophon Therapeutics during the second quarter valued at about $271,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Bellerophon Therapeutics during the second quarter valued at about $146,000. Finally, American International Group Inc. purchased a new position in shares of Bellerophon Therapeutics during the second quarter valued at about $26,000. 40.22% of the stock is owned by institutional investors.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Featured Story: How to Use a Moving Average for TradingĀ 

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.